Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2017 (2017), Article ID 5952149, 6 pages
https://doi.org/10.1155/2017/5952149
Research Article

Accumulation of α-Synuclein in Cerebellar Purkinje Cells of Diabetic Rats and Its Potential Relationship with Inflammation and Oxidative Stress Markers

1Department of Neurology, Trakya University Faculty of Medicine, Edirne, Turkey
2Department of Physiology, Kafkas University Faculty of Medicine, Kars, Turkey
3Department of Histology and Embryology, Ege University Faculty of Medicine, Izmir, Turkey
4Department of Physiology, Bilim University Faculty of Medicine, Istanbul, Turkey
5Department of Physiology, Ege University Faculty of Medicine, Izmir, Turkey

Correspondence should be addressed to Dilek Taşkıran; rt.ude.ege@nariksat.kelid

Received 29 August 2016; Accepted 20 December 2016; Published 4 January 2017

Academic Editor: Mamede de Carvalho

Copyright © 2017 Volkan Solmaz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Power, “Standards of medical care in diabetes: response to position statement of the American Diabetes Association,” Diabetes Care, vol. 29, no. 2, p. 476, 2006. View at Publisher · View at Google Scholar
  2. E. Selvin, C. M. Parrinello, D. B. Sacks, and J. Coresh, “Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999-2010,” Annals of Internal Medicine, vol. 160, no. 8, pp. 517–525, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Nagayach, N. Patro, and I. Patro, “Experimentally induced diabetes causes glial activation, glutamate toxicity and cellular damage leading to changes in motor function,” Frontiers in Cellular Neuroscience, vol. 8, article 355, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Yang, C. Xia, S. Li, L. Du, L. Zhang, and Y. Hu, “Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model,” Cell Death and Disease, vol. 5, no. 5, Article ID e1217, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Ates, S. R. Cayli, E. Altinoz et al., “Neuroprotective effect of mexiletine in the central nervous system of diabetic rats,” Molecular and Cellular Biochemistry, vol. 286, no. 1-2, pp. 125–131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Corti, S. Lesage, and A. Brice, “What genetics tells us about the causes and mechanisms of Parkinson's disease,” Physiological Reviews, vol. 91, no. 4, pp. 1161–1218, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Kara, D. Unal, N. Simsek, A. Yucel, N. Yucel, and J. Selli, “Ultra-structural changes and apoptotic activity in cerebellum of post-menopausal-diabetic rats: a histochemical and ultra-structural study,” Gynecological Endocrinology, vol. 30, no. 3, pp. 226–231, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. T. F. Outeiro, P. Putcha, J. E. Tetzlaff et al., “Formation of toxic oligomeric α-synuclein species in living cells,” PLoS ONE, vol. 3, no. 4, Article ID e1867, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Iwai, E. Masliah, M. Yoshimoto et al., “The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system,” Neuron, vol. 14, no. 2, pp. 467–475, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. M. G. Spillantini, M. L. Schmidt, V. M.-Y. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, “α-synuclein in Lewy bodies [8],” Nature, vol. 388, no. 6645, pp. 839–840, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. A. B. Singleton, M. Farrer, J. Johnson et al., “α-synuclein locus triplication causes Parkinson's disease,” Science, vol. 302, no. 5646, p. 841, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M.-C. Chartier-Harlin, J. Kachergus, C. Roumier et al., “α-synuclein locus duplication as a cause of familial Parkinson's disease,” Lancet, vol. 364, no. 9440, pp. 1167–1169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Klegeris and P. L. McGeer, “Complement activation by islet amyloid polypeptide (IAPP) and α-synuclein 112,” Biochemical and Biophysical Research Communications, vol. 357, no. 4, pp. 1096–1099, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Fatima, R. Haque, P. Jadiya, Shamsuzzama, L. Kumar, and A. Nazir, “Ida-1, the caenorhabditis elegans orthologue of mammalian diabetes autoantigen IA-2, potentially acts as a common modulator between Parkinson's disease and diabetes: role of Daf-2/Daf-16 insulin like signalling pathway,” PLoS ONE, vol. 9, no. 12, Article ID e113986, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Rajkovic, A. Denes, S. M. Allan, and E. Pinteaux, “Emerging roles of the acute phase protein pentraxin-3 during central nervous system disorders,” Journal of Neuroimmunology, vol. 292, pp. 27–33, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Demougeot, C. Marie, and A. Beley, “Importance of iron location in iron-induced hydroxyl radical production by brain slices,” Life Sciences, vol. 67, no. 4, pp. 399–410, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. G. L. Ellman, “Tissue sulfhydryl groups,” Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Liu, C. Zhang, J. Yin et al., “α-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity,” Neuroscience Letters, vol. 454, no. 3, pp. 187–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Narayanan and S. Scarlata, “Membrane binding and self-association of α-synucleins,” Biochemistry, vol. 40, no. 33, pp. 9927–9934, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Mori, Y.-S. Piao, S. Hayashi et al., “α-Synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 8, pp. 812–819, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Sebeo, P. R. Hof, and D. P. Perl, “Occurrence of α-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex,” Acta Neuropathologica, vol. 107, no. 6, pp. 497–503, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Baydas, R. J. Reiter, A. Yasar, M. Tuzcu, I. Akdemir, and V. S. Nedzvetskii, “Melatonin reduces glial reactivity in the hippocampus, cortex, and cerebellum of streptozotocin-induced diabetic rats,” Free Radical Biology and Medicine, vol. 35, no. 7, pp. 797–804, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. N. G. Ozdemir, F. Akbas, T. Kotil, and A. Yılmaz, “Analysis of diabetes related cerebellar changes in streptozotocin-induced diabetic rats,” Turkish Journal of Medical Sciences, vol. 46, no. 5, pp. 1579–1592, 2016. View at Google Scholar
  24. D. H. Bak, E. Zhang, M.-H. Yi et al., “High ω3-polyunsaturated fatty acids in fat-1 mice prevent streptozotocin-induced Purkinje cell degeneration through BDNF-mediated autophagy,” Scientific Reports, vol. 5, Article ID 15465, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. J. A. Santiago and J. A. Potashkin, “Shared dysregulated pathways lead to Parkinson's disease and diabetes,” Trends in Molecular Medicine, vol. 19, no. 3, pp. 176–186, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Braak, K. Del Tredici, U. Rüb, R. A. I. de Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson's disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Wang, Y.-Q. Zhai, L.-L. Xu et al., “Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice,” Experimental Neurology, vol. 251, pp. 22–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Xie, F. Lin, K. Ullah et al., “A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease,” Biochemical and Biophysical Research Communications, vol. 459, no. 3, pp. 361–366, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Giacco and M. Brownlee, “Oxidative stress and diabetic complications,” Circulation Research, vol. 107, no. 9, pp. 1058–1070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. B. K. Tiwari, K. B. Pandey, A. B. Abidi, and S. I. Rizvi, “Markers of oxidative stress during diabetes mellitus,” Journal of Biomarkers, vol. 2013, Article ID 378790, 8 pages, 2013. View at Publisher · View at Google Scholar
  31. N. Fatima, S. M. Faisal, S. Zubair et al., “Role of pro-inflammatory cytokines and biochemical markers in the pathogenesis of type 1 diabetes: correlation with age and glycemic condition in diabetic human subjects,” PLOS ONE, vol. 11, no. 8, Article ID e0161548, 2016. View at Publisher · View at Google Scholar
  32. O. Erbaş, F. Oltulu, M. Yılmaz, A. Yavaşoğlu, and D. Taşkıran, “Neuroprotective effects of chronic administration of levetiracetam in a rat model of diabetic neuropathy,” Diabetes Research and Clinical Practice, vol. 114, pp. 106–116, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. S. A. Moussa, “Oxidative stress in diabetes mellitus,” Romanian Journal of Biophysics, vol. 18, pp. 225–236, 2008. View at Google Scholar
  34. W. Zhou and W. Hu, “Serum and vitreous pentraxin 3 concentrations in patients with diabetic retinopathy,” Genetic Testing and Molecular Biomarkers, vol. 20, no. 3, pp. 149–153, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. H. S. Yang, J. E. Woo, S. J. Lee, S. H. Park, and J. M. Woo, “Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in korean patients with type 2 diabetes mellitus,” Investigative Ophthalmology and Visual Science, vol. 55, no. 9, pp. 5989–5997, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Ceylan, O. F. Bayraktutan, S. Becel, Ö. Atis, A. Yalcin, and D. Kotan, “Serum levels of pentraxin-3 and other inflammatory biomarkers in migraine: association with migraine characteristics,” Cephalalgia, vol. 36, no. 6, pp. 518–525, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Shindo, T. Maki, E. T. Mandeville et al., “Astrocyte-derived pentraxin 3 supports blood-brain barrier integrity under acute phase of stroke,” Stroke, vol. 47, no. 4, pp. 1094–1100, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. H.-W. Lee, J. Choi, and K. Suk, “Increases of pentraxin 3 plasma levels in patients with Parkinson's disease,” Movement Disorders, vol. 26, no. 13, pp. 2364–2370, 2011. View at Publisher · View at Google Scholar · View at Scopus